ACOG Fundamental Analysis - ALPHA COGNITION INC

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to ACOG. ACOG was compared to 547 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ACOG as it has an excellent financial health rating, but there are worries on the profitability. ACOG is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ACOG had negative earnings in the past year.

ACOG had a negative operating cash flow in the past year.

In the past 5 years ACOG always reported negative net income.

In the past 5 years ACOG always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -44.35%, ACOG is in line with its industry, outperforming 54.84% of the companies in the same industry.

ACOG's Return On Equity of -62.75% is fine compared to the rest of the industry. ACOG outperforms 60.33% of its industry peers.

		Industry Rank	Sector Rank
ROA	-44.35%
ROE	-62.75%
ROIC	N/A

ROA(3y)-333.55%

ROA(5y)-244.19%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ACOG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for ACOG has been increased compared to 1 year ago.

ACOG has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 3.44 indicates that ACOG is not in any danger for bankruptcy at the moment.

With a decent Altman-Z score value of 3.44, ACOG is doing good in the industry, outperforming 74.41% of the companies in the same industry.

ACOG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	3.44

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ACOG has a Current Ratio of 14.69. This indicates that ACOG is financially healthy and has no problem in meeting its short term obligations.

ACOG has a better Current ratio (14.69) than 89.58% of its industry peers.

ACOG has a Quick Ratio of 14.40. This indicates that ACOG is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 14.40, ACOG belongs to the top of the industry, outperforming 89.40% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	14.69
Quick Ratio	14.4

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 38.08% over the past year.

EPS 1Y (TTM)38.08%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-160%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

ACOG is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -275.00% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-1706.25%

EPS Next 2Y-275%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ACOG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ACOG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ACOG's earnings are expected to decrease with -275.00% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-275%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ACOG!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ALPHA COGNITION INC

NASDAQ:ACOG (8/27/2025, 8:00:01 PM)

8.24

+0.31 (+3.91%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-18 2025-08-18/dmh

Earnings (Next)N/A N/A

Inst Owners41.72%

Inst Owner ChangeN/A

Ins Owners13.07%

Ins Owner Change-5.15%

Market Cap133.16M

Analysts82.86

Price Target20.4 (147.57%)

Short Float %0.91%

Short Ratio1.99

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)26.54%

Min EPS beat(2)-24.95%

Max EPS beat(2)78.03%

EPS beat(4)2

Avg EPS beat(4)36.98%

Min EPS beat(4)-24.95%

Max EPS beat(4)99.02%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)14.4%

Min Revenue beat(2)-14.76%

Max Revenue beat(2)43.56%

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)-10.87%

EPS NQ rev (3m)39.29%

EPS NY rev (1m)-2.12%

EPS NY rev (3m)50.68%

Revenue NQ rev (1m)15.09%

Revenue NQ rev (3m)99.78%

Revenue NY rev (1m)0%

Revenue NY rev (3m)37.67%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	29.03
P/FCF	N/A
P/OCF	N/A
P/B	4.17
P/tB	4.23
EV/EBITDA	N/A

EPS(TTM)-1.3

EYN/A

EPS(NY)-1.15

Fwd EYN/A

FCF(TTM)-0.75

FCFYN/A

OCF(TTM)-0.75

OCFYN/A

SpS0.28

BVpS1.97

TBVpS1.95

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-44.35%
ROE	-62.75%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-333.55%

ROA(5y)-244.19%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.1

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	14.69
Quick Ratio	14.4
Altman-Z	3.44

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)12.76%

Cap/Depr(5y)24.09%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)38.08%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-160%

EPS Next Y-1706.25%

EPS Next 2Y-275%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-20.22%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year124.69%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y11.56%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y11.86%

OCF growth 3YN/A

OCF growth 5YN/A

ALPHA COGNITION INC (ACOG) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens